+ acute B-lymphoblastic leukemia (B-ALL) is a disease associated with a dismal prognosis and a high incidence of central nervous system (CNS) metastasis. However, BCR-ABL1 + B-ALL with CNS infiltration has not been previously characterized, at least to the best of our knowledge. In the present study, a murine model of BCR-ABL1 + B-ALL with CNS metastasis was established using retroviral transduction. The vast majority of BCR-ABL1 + leukemic cells were found to be immature B cells with a variable proportion of pro-B and pre-B populations. The present results indicated that the BCR-ABL1 + B-leukemic cells expressed high levels integrin subunit alpha 6 (Itga6) and L-selectin adhesion molecules, and have an intrinsic ability to disseminate and accumulate in CNS tissues, predominantly in meninges. On the whole, these results provide an approach for addressing the mechanisms of BCR-ABL1 + B-ALL with CNS metastasis and may guide the development of novel therapeutic strategies.
Introduction

Breakpoint cluster region (BCR)-Abelson murine leukemia (ABL)1
+ acute B-lymphoblastic leukemia (B-ALL) is characterized by the presence of the Philadelphia chromosome arising from the t(9;22)(q34;q11.2) translocation (1) . The fusion gene constitutively encodes BCR-ABL1 tyrosine kinase, which activates its downstream signaling molecules/ pathways (2) . The accentuation of these pathways leads to the arrest of B-cell differentiation at an immature stage (progenitor or precursor), followed by uncontrolled proliferation and invasion (3) . The use of tyrosine kinase inhibitors (TKIs) is the most effective method for suppressing BCR-ABL1 tyrosine kinase activity (4, 5) . However, single-agent TKI has not produced sustained responses in BCR-ABL1 + B-ALL, as this specific subtype of B-ALL is likely to develop significant involvement of the CNS, which acts as a 'sanctuary' site for leukemic cells to escape anticancer treatments (6) (7) (8) . Therefore, understanding the molecular mechanisms of BCR-ABL1 + B-ALL associated with CNS metastasis is a critical step to improve therapeutics.
Previous studies have reported that leukemia follows a blood-vessel track to enter the nervous system, indicating that lymphocytes and leukemic cells may share similar mechanisms of dissemination into tissues (9, 10) . These cells leave the blood circulation and enter extramedullary tissues by extravasation (9) . Following selectin-mediated rolling, cells adhere to endothelial vascular walls by chemokine-and integrin-mediated adhesion to the endothelium (11) . Subsequently, lymphocytes and leukemic cells cross the endothelial barrier via transendothelial migration (12, 13) . The morphological changes and mechanical force required to cross the endothelial barrier rely on integrins and adhesion molecules expressed on lymphocytes or leukemic cells (7, 10) . These phenomena imply that BCR-ABL1 + leukemic cells also have the ability to enter and disseminate into the CNS. The BCR-ABL1 retroviral bone marrow transduction/transplantation model and the human xenograft NOD/severe combined immunodeficiency (SCID) mouse model are widely used to investigate the mechanisms (14, 15) . However, the characteristics of BCR-ABL1 + B-ALL with CNS metastasis have not been previously investigated, at least to the best of our knowledge.
In the present study, the experimental procedure of BCR-ABL1 retroviral transduction was employed to establish a murine model of BCR-ABL1 + B-ALL with CNS metastasis. The BCR-ABL1 + leukemic cells have an immature B-cell phenotype, including pro-B and pre-B populations with a high expression of integrin subunit alpha 6 (Itga6) and L-selectin adhesion molecules. BCR-ABL1
+ leukemic B cells were observed to predominantly invade the meninges, medulla oblongata, cerebrum, cerebellum and lumbar spinal cord. The present results demonstrate that BCR-ABL1 + B-ALL with CNS metastasis is dependent on the intrinsic infiltration ability of BCR-ABL1 + cells, but is independent on increased vascular permeability and structural damage. The present study provides a suitable murine model for studying BCR-ABL1-dependent leukemogenesis and may aid in the development of novel therapeutic strategies for B-ALL disorders.
Materials and methods
Retroviral construction. Murine stem cell virus (MSCV)
vector co-expressing human BCR-ABL1 (p210) and green fluorescence protein (GFP; MSCV-BCR-ABL1-IRES-GFP, MIG-p210) and MSCV vector expressing GFP (MIG) have been previously described (16) . K562 cells were cultured at 37˚C with 5% CO 2 in RPMI-1640 (HyClone; Thermo Fisher Scientific, Inc.) medium supplemented with 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.). 293T cells were cultured at 37˚C with 5% CO 2 in DMEM (HyClone; Thermo Fisher Scientific, Inc.) medium supplemented with 10% fetal calf serum. 293T cells were transfected with PKAT2 packaging vector and MIG-p210 or MIG using X-tremeGENE HP DNA Transfection reagent (Roche), respectively. At 48 h following transfection, viral supernatants were collected, filtered and stored at -80˚C. K562 and 293T cells were kindly provided by Professor Yanmin Zhang (Xi'an Jiaotong University Health Science Centre).
Bone marrow transduction/transplantation. As previously described (14, 15) , experimental C57BL/6 mice (age, 7-10 weeks; weight, ~18 g) were purchased from the Experimental Animal Center of Xi'an Jiaotong University and allowed to acclimatize to the environment under specific pathogen-free conditions. The donors (males) and recipients (females) were of the same mouse strain. All animal experiments were performed according to the guidelines of and were approved by the Institutional Animal Care and Use Committee of Xi'an Jiaotong University. In brief, in order to induce ALL, femurs and tibias collected from the donor mice were placed in cold PBS, clipped of the end of the bone, and bone marrow cells were flushed out with PBS. Cells were spun down at 200 x g for 10 min at 4˚C and the supernatant was removed. Bone marrow cells from 2 donor C57BL/6 mice without 5-fluorouracil treatment were subjected to a single round of co-sedimentation with MIG-p210 retroviral supernatants supplemented with 5% WEHI-3B-conditioned medium, 10 ng/ ml interleukin (IL)-7 (PeproTech, Inc.) and 20 µg/ml polybrene (Beijing Solarbio Science and Technology Co., Ltd.). The cells were collected 2 h later, washed once in HBSS (Beijing Solarbio Science and Technology Co., Ltd.) and transplanted into lethally irradiated (2x460 cGy) syngeneic 6 female recipient mice (1x10 6 cells each) or subjected to culture in RPMI-1640 medium (HyClone, Thermo Fisher Scientific, Inc.) supplemented with 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.), 200 µmol/l L-glutamine, 50 µmol/l 2-mercaptoethanol (Amersco, Inc., Cleveland, OH, USA) and penicillin/streptomycin (HyClone, Thermo Fisher Scientific, Inc.) for 48 h. For the control group, bone marrow cells from 1 donor C57BL/6 mouse were subjected to co-sedimentation with MIG retroviral supernatants and transplanted into 3 recipient mice (details were the same as mentioned above). A GFP + cell population of >10% was considered to indicate successful transduction. When the transplanted recipient mice exhibited clinical signs of leukemia, which included weight loss, failure to thrive, limb paralysis and splenomegaly, they were euthanized. For secondary transplantation, 1x10 6 , 1x10 5 and 1x10 4 bone marrow cells from primary BCR-ABL1 + ALL mice were transplanted into non-irradiated recipient mice, respectively. The secondary transplant recipients were monitored for clinical signs of leukemia as mentioned above for euthanization. (1:20 dilution; cat. no. 551001; BD Biosciences) for cell lineages, and incubated with anti-CD43-PE (1:20 dilution; cat. no. 553271; BD Biosciences) and anti-B220-APC (1:20 dilution; cat. no. 553092; BD Biosciences) antibodies for B-cell development. The cells were incubated with the antibodies for 20 min at 4˚C. Analysis was performed using CytoFLEX flow cytometer and the data were analyzed with CytExpert 2.1 (Beckman Coulter, lnc.).
Histology. Mice were anesthetised with chloral hydrate (500 mg/kg) by intraperitoneal injection and the mice were monitored for the absence of tail, foot and ear reflexes, as well as a reduced respiratory rate, which are all indications of effective anesthesia (17) . The mice were firstly perfused with 0.9% saline and then with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brain and spinal cord tissues were harvested and post-fixed in 4% paraformaldehyde for 4-6 h at 4˚C. The tissues were then dehydrated in 30% sucrose. All the tissues were embedded in Tek Optimal Cutting Temperature compound (Sakura Finetek Japan Co., Ltd.), sectioned with a semiconductor freezing microtome and stained with hematoxylin and eosin (H&E). For H&E staining (cat. no. G1005; Wuhan Servicebio Co., Ltd.) the slides were washed in PBS and stained with Harris's hematoxylin (10%) for 3-8 min and eosin (70%) for 1-3 min at room temperature. Subsequently, the sections were dehydrated through an increasing concentration of ethanol and xylene. Images of H&E staining were captured using a Zeiss Axio Scope. A1 microscope (Carl Zeiss Microscopy GmbH).
Wright-Giemsa staining. A 10 µl aliquot of peripheral blood or bone marrow cell flushed out with PBS was spread on a slide to produce a smear and dried at room temperature for 30 min. The smear was fixed with methanol for 15 min and dried at room temperature. The smear was stained with Wright-Giemsa Stain (Heart Biological Technology Co., Ltd) for 8 min at room temperature and was then rinsed with water until the edges turned a pinkish-red color. After air-drying, the smear was inspected under a Zeiss Axio Scope. A1 microscope (Carl Zeiss Microscopy GmbH).
Analysis of CNS metastasis of leukemia by intravascular labeling. Individual BCR-ABL1
+ B-ALL mice were intravenously injected with 3 mg anti-CD19-PerCP-Cy TM5.5 , at 4 min prior to CO 2 euthanasia (flow rate of CO 2 used for the euthanasia of the mice was displaced 20% of the chamber volume per min). Blood was then harvested by cardiocentesis, and mice were subsequently perfused with saline to eliminate residual blood in vessels within tissues (18) . The cerebrum, cerebellum, medulla oblongata, meninges, thoracic spinal cord and lumbar spinal cord were dissected and mechanically processed to obtain a single-cell suspension. The samples were examined for GFP and CD19 expression by flow cytometry. (19) . The following the forward and reverse primers were used: Itga6 5'-GAT CCC GGG AGC CTC TTC-3' and 5'-GAT GTC ACA GCT GTA CA GGC-3'; L-selectin, 5'-CTT ACT GGG GCT CGA GGA AC-3' and 5'-TCT CTC TTG TTT TGT ATG GCG AC-3'; GAPDH, 5'-CGT CCC GTA GAC AAA ATG GT-3' and 5'-AGG TCA ATG AAG GGG TCG TT-3'.
Statistical analysis. Statistical analysis was performed using SPSS 20.0 (IBM Corp.) and GraphPad Prism 6.0 (GraphPad Software). For continuous variables, descriptive results were presented as the means ± standard error of the mean (SEM). Levene's test was used for equality of variances. The independent-samples t-test, one-way analyses of variance (ANOVA) with post-hoc Fisher's LSD test and log-rank Mantel-Cox analysis were performed for 2-group comparisons, multiple groups comparisons and survival comparisons, respectively. Kaplan-Meier survival curves wereused to describe the changes of survival rate with time. P<0.05 was considered to indicate a statistically significant difference.
Results
Establishment of a murine model of BCR-ABL1
+ ALL with extramedullary hematopoietic site infiltration. To generate a murine model of BCR-ABL1 + ALL with metastasis, 1x10 6 bone marrow cells harvested from donor mice were subjected to co-sedimentation with a retrovirus co-expressing BCR-ABL1 and GFP, and then transplanted into syngeneic lethally irradiated recipient mice. Of the primary recipients, 100% exhibited symptoms of clinical leukemia with hind limb paralysis to various degrees or other observable CNS symptoms, weight loss, respiratory or other types of distress, or extreme lethargy. The leukemic mice were euthanized from 40 to 83 days following transplantation (Fig. 1A-C) . As a result of cachexia, the maximum percentage of body weight loss observed in the leukemic mice was 15.23% (Fig. 1C) . The peripheral blood contained lymphoblastic cells with 32.00% GFP + cells (Fig. 1D) . The bone marrow cells appeared to be of a lymphoblastic phenotype with 43.49% GFP + cells (Fig. 1E) . The leukemic mice developed splenomegaly with 54.21% GFP + cells (Fig. 1F) and lymphadenopathy with 86.83% GFP + cells (Fig. 1G) . These results indicate that the transplanted mice developed classical ALL. Furthermore, BCR-ABL1 + leukemic cells were observed to metastasize to the subcutaneous tissues, lung and liver with varying amounts of GFP + cells ( Fig. 2A-C and Table I ). Of note, the degree of infiltration into the lymph nodes and subcutaneous tissues was significantly higher compared with that into other tissues in the BCR-ABL1 + ALL mice (Figs. 1H and 2D ). BCR-ABL1 expression were detected in the bone marrow, spleen and subcutaneous tissues (Fig. 2E) . Taken together, these results demonstrate that the mouse model of BCR-ABL1 + ALL with infiltration into non-hematopoietic tissues was successfully established by using the BCR-ABL1 retroviral transduction system.
BCR-ABL1
+ lymphoblastic cells with respect to their phenotype and lineage origin, it was examined whether BCR-ABL1 + leukemic cells were lineage-specific. The bone marrow or spleen cells from leukemic mice were incubated with antibodies against Gr1 for myeloid cells, CD3 for T-lymphoid cells and CD19 for B-lymphoid cells, respectively, and analyzed by flow cytometry. The results indicated that GFP + cells derived from individual leukemic mice expressed the B lymphoid-specific marker CD19, but not CD3 or Gr1 (Fig. 3A and B, and Fig. S1A and B) , suggesting that the BCR-ABL1 + leukemic cells were of the B-cell lineage. To evaluate the B-cell development stage of the leukemic GFP + CD19 + population, the CD43-and B220-expressing cells among GFP + cells were gated. The results indicated that GFP + cells contained a variable proportion of CD43 and B220 populations ( Fig. 3C and D, and 
BCR-ABL1 + B-ALL leukemic cells invade the CNS. Since the BCR-ABL1
+ B-ALL mice exhibited severe CNS symptoms, the lumbar spinal cord and cerebellar tissues were first dissected for H&E staining in the BCR-ABL1 + B-ALL mice and healthy control mice, respectively. The histological sections revealed a significant number of leukemic cells in the lumbar spinal cord and meninges of the BCR-ABL1 + B-ALL mice compared to the healthy controls (Fig. 4) , suggesting that the BCR-ABL1 + cells had already invaded into the CNS when the leukemic mice developed clinical symptoms of limb paralysis.
Subsequently, to identify the exact proportions of leukemic infiltration in the nervous system, an intravascular staining approach was pursued. First, the anti-CD19 antibody was injected into the vasculature of BCR-ABL1 + B-ALL mice and the blood was then harvested immediately. The leukemic mouse was perfused with saline to remove residual blood cells and anti-CD19 antibody after euthanasia. The single-cell suspension was collected from the blood, brain parenchyma, meninges and spinal cord, and further analyzed for GFP and CD19 expression. The BCR-ABL1 + B-ALL leukemic cells in the vasculature revealed a GFP + CD19 + population, as the cells were stained by anti-CD19 antibody (Fig. 5A) . The leukemic cells that had infiltrated into the CNS had no opportunity to be stained by anti-CD19 antibody and were only GFP + , and their proportion varied between the meninges (72.70%), lumbar spinal cord (8.84%), medulla oblongata (4.25%), cerebrum (4.14%) and cerebellum (3.25%; Fig. 5B and C) , which was in agreement with the observation from H&E staining that massive leukemic cell infiltration had occurred in the meninges. In addition, no infiltration in the thoracic spinal cord was observed, indicating that the leukemic cells in the lumbar spinal cord probably did not originate from the spreading of CNS residual leukemia by extension along spinal nerves. These results suggest that the BCR-ABL1 + B-ALL cells have the ability to enter and disseminate into the CNS.
BCR-ABL1 + B-ALL leukemic cell invasion into the CNS is dependent on their own intrinsic properties. To further confirm whether the BCR-ABL1
+ B-ALL with CNS metastasis was driven by the ability of leukemic cells to enter and disseminate into the CNS, experiments were performed using immunocompetent recipient mice injected with 1x10 6 , 1x10 5 or 1x10 4 primary BCR-ABL1 + leukemic cells. Irradiation-induced CNS damage was avoided through this injection. It was observed that the secondary recipients developed BCR-ABL1 + leukemia with severe paralysis of their hind limbs within 25 days following transplantation ( Fig. 6A and B) . The onset of secondary leukemia was shorter in comparison with that of primary leukemia (Fig. 1A) . The morphological lymphoblastic cells were enriched in the peripheral blood and bone marrow (Fig. 6C and D) . The immunophenotype of GFP + cells displayed a B-cell lineage with block at pro-B to pre-B stages of B-cell development (Fig. 6E) . Of note, the percentage of GFP + cells in the CNS of secondary BCR-ABL1 + B-ALL was significantly increased when compared to that in primary B-ALL (Fig. 6F) . These results re-emphasize that BCR-ABL1 + leukemogenic cells have their own intrinsic properties to induce B-ALL with a high incidence of CNS infiltration.
It was hypothesized that the molecules associated with adhesion are deregulated in BCR-ABL1 + B-ALL mice (20) . The expression of cell adhesion molecule Itga6 and L-selectin was detected in splenic GFP + CD19 + cells sorted from primary and secondary BCR-ABL1 + B-ALL mice. The splenic CD19 + cells derived from healthy mice were used as controls. The results indicated that the transcripts of Itga6 and L-selectin were upregulated in primary and secondary BCR-ABL1 + B-ALL compared with those in healthy control mice, respectively ( Fig. 6G and Fig. S2) . Furthermore, the expression levels of Itga6 and L-selectin were also significantly increased in the secondary BCR-ABL1 + B-ALL mice compared with those in the primary ones. These results may imply that in BCR-ABL1 + B-ALL mice, the invasion of BCR-ABL1 + leukemic cells into the CNS probably depends on abnormal gene expression associated with metastasis.
Discussion
BCR-ABL1 + B-ALL has a poor prognosis and is associated with refractoriness and CNS damage (21) (22) (23) (24) . Current disease Previous studies have been reported that approximately 30-50% of patients with BCR-ABL1 + ALL harbor the p210 fusion protein, with the remaining 50-70% being characterized by the p190 fusion protein (25) . The BCR-ABL1 fusion oncogene exists in two principal forms (p190 and p210) that arise from distinct breakpoints in the BCR gene on chromosome 22, resulting in translocation of BCR exon 1 or exons 1-12/13, respectively, to the c-ABL1 gene on chromosome 9. p210 and p190 contain the same portion of the c-ABL1 tyrosine kinase and acquire uncontrolled tyrosine kinase activity, both of which constantly turn on the downstream signaling molecules/pathways, and promoting proliferation of leukemia cells (16) . Previous studies have reported that chronic myeloid leukemia (CML) can be reproduced in mice by the retroviral transduction of p190 or p210 into hematopoietic stem cell (HSC)-enriched bone marrow (BM) cells in the presence of myeloid cytokines, followed by transplantation into irradiated recipients (14, 26) , which is a myeloproliferative disorder characterized by the increased proliferation of granulocytic cells without the loss of their capability to differentiate (27) (28) (29) (30) .
In the present study, this approach was utilized by donor bone marrow cells pre-stimulated with the lymphoid cytokine IL-7, which provides critical signals for B-cell proliferation and survival (31, 32) . As a result, the mouse p210 + B-ALL mouse model was not only successfully generated, but it was also observed that prominent infiltration in non-hematopoietic tissues with clinical severe paralysis of CNS was achieved. The present results indicated that the majority of the leukemic cells may be characterized as immature pro-B (CD43 + B220 + ) and pre-B (CD43 -B220 + ) populations (33) (34) (35) (36) . In addition to this observation, rare GFP + cells, either from the bone marrow or spleen, lacked expression of lineage-specific antigens (data not shown), implying that the BCR-ABL1 + B-ALL cells contain leukemic stem and progenitor cells and propagate leukemia to the next generation. It was also demonstrated that the transplantation of primary BCR-ABL1 + B-ALL cells is capable of generating secondary B-ALL in non-irradiated mice. This murine model resembles human BCR-ABL1 + B-ALL and may be used to study the prognosis of human B-ALL.
The model established in the present study has an attractive feature of enabling leukemic cells to expand into various types of non-hematopoietic tissue, including the CNS, subcutaneous tissue, lung and liver. H&E staining and intravascular staining technology were applied to precisely assess the exact portions of leukemic cells dissemination into CNS. The results suggest that leukemic cells are predominantly deposited in the meninges, medulla oblongata, cerebrum, lumbar spinal cord and cerebellum, which is consistent with the results of previous studies (37) (38) (39) . A previous study detected small vessels transiting between the bone marrow and subarachnoid space in leukemic mice, and it was indicated that numerous openings in the vertebral cortical bone were filled with ALL cells, which appeared to be in transit between the bone marrow involved and the subarachnoid space (13, 40) . Therefore, BCR-ABL1 + leukemic cells may directly metastasize into the lumbar spinal cord, but not into the thoracic spinal cord.
Laminin is localized in the extracellular matrix of meninges, the choroid plexus and peripheral nerve sheaths in the nervous system (41, 42) . Metastasis to the CNS has been indicated to be mediated through the interaction of molecules associated with cell motility and adhesion (43) . This information supports the present result that highly expressed Itga6 and L-selectin may allow BCR-ABL1 + B-ALL leukemic cells to interact with laminin located in the ECM of meninges. This specific interaction hijacks and recruits leukemic cells into the meninges, but fails to enter the brain parenchyma (7, 12, 42, 43) . These results support the phenomenon that a large number of leukemic cells accumulate in the meninges.
In conclusion, in the present study, a murine model of BCR-ABL1 + B-ALL with CNS metastasis was generated. The infiltrated BCR-ABL1 + immature B cells have the ability to metastasize in various proportions into the CNS, with significant accumulation in the meninges, which may be associated with the upregulation of numerous adhesion molecules, including Itga6 and L-selectin. These results encourage further studies to address whether TKIs combined with the targeting of proteins associated with cell migration and adhesion may offer a therapeutic approach for the CNS metastasis/relapse of BCR-ABL1 + B-ALL.
